Abiopharma

🔍 COWARD D SCOTT (Executive)

Company: EXACT SCIENCES CORP (EXAS)

Report Date: 2026-03-23

Detailed Transactions and Holdings:

• Sold 52,164 shares of Common Stock (Direct)
  Date: 2026-03-23 | Code: D | equity_swap_involved: false | shares_owned_after: 5,398.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 5,398 shares of Common Stock (Direct)
  Date: 2026-03-23 | Code: D | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F2
• Sold 4,694 shares of Common Stock (Direct)
  Date: 2026-03-23 | Code: D | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1
• Sold 4,175 shares of Stock Options (Right to Buy) at $44.37 per share (Derivative)
  Date: 2026-03-23 | Code: D | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F4, F3, F3
• Sold 10,786 shares of Stock Options (Right to Buy) at $92.62 per share (Derivative)
  Date: 2026-03-23 | Code: D | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F4, F5, F5
• Sold 12,875 shares of Stock Options (Right to Buy) at $98.18 per share (Derivative)
  Date: 2026-03-23 | Code: D | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F4, F6, F6

Footnotes:

• F1: On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration").
• F2: At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding.
• F3: These options became exercisable on February 27, 2022.
• F4: At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding
• F5: These options became exercisable on February 26, 2023.
• F6: These options became exercisable on February 14, 2024.